<?xml version="1.0" encoding="UTF-8"?>
<p>In summary, this study presents a promising case for the development of a novel therapeutic targeting Ca
 <sub>v</sub>3.3. However, further testing in other models of neuropathic pain and eventually in primates will be required to determine if Ca
 <sub>v</sub>3.3-blockade is an effective strategy for treatment in patients with trigeminal neuropathic pain.
</p>
